PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, PROVECTUS BIOPHARMACEUTICALS, INC. reported revenue of $336.1K, down 45.5% from the prior year. The company ran a net loss, with a net margin of -1615.8%. It held $697.5K in total assets against $7.00M in total liabilities.
Key ratios (FY2025)
-1575.3%
Operating margin
-1615.8%
Net margin
-45.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $336.1K | $617.1K | $557.7K | $989.0K | — | — | — | — | — | — |
| Operating Income | -$5.29M | -$4.53M | -$2.90M | -$3.43M | -$4.67M | -$4.96M | -$6.30M | -$8.05M | -$13.32M | -$24.51M |
| Net Income | -$5.43M | -$4.73M | -$3.10M | -$3.55M | -$5.54M | -$6.68M | -$6.92M | -$8.15M | -$13.52M | -$24.43M |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | — | — | — | — | — |
| Total Assets | $697.5K | $1.01M | $1.45M | $2.04M | $3.51M | $589.2K | $1.48M | $1.99M | $3.44M | $5.61M |
| Total Liabilities | $7.00M | $6.98M | $9.04M | $8.27M | $7.70M | $30.80M | $25.55M | $19.41M | $13.46M | $2.14M |
| Shareholders' Equity | -$6.30M | -$5.96M | -$7.59M | -$6.23M | -$4.19M | -$30.21M | -$24.07M | -$17.42M | -$10.02M | $3.47M |
| Cash & Equivalents | $251.3K | $307.4K | $76.6K | $21.6K | $683.0K | $97.2K | $590.7K | $51.0K | $105.5K | $1.17M |
| Operating Cash Flow | -$3.33M | -$3.28M | -$2.57M | -$3.04M | -$1.01M | -$4.09M | -$6.19M | -$5.20M | -$10.35M | — |
| Capital Expenditures | — | — | — | — | — | — | — | — | $30.4K | — |
| Shares Outstanding | 420.28M | 420.28M | 419.52M | 419.45M | 419.45M | 398.81M | 389.89M | 384.61M | 370.96M | 364.77M |